Panacea finds no cure-all for its financial woes
This article was originally published in Scrip
Executive Summary
Panacea Biotec, India's second largest vaccine producer, finds itself in an unenviable financial position with substantial net worth erosion, highlighting what some experts say are the perils of dependence on "binary" tender-based bulk purchases.